SEC Form S-1/A filed by TradeUP Acquisition Corp. (Amendment)
$UPTD
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
3 - Estrella Immunopharma, Inc. (0001844417) (Issuer)
3 - Estrella Immunopharma, Inc. (0001844417) (Issuer)
3 - Estrella Immunopharma, Inc. (0001844417) (Issuer)
10-Q - Estrella Immunopharma, Inc. (0001844417) (Filer)
424B3 - Estrella Immunopharma, Inc. (0001844417) (Filer)
8-K - Estrella Immunopharma, Inc. (0001844417) (Filer)
Estrella to Begin Trading on NASDAQ Under the Ticker Symbols "ESLA" and "ESLAW" Beginning October 2, 2023 NEW YORK, Sept. 29, 2023 /PRNewswire/ -- Estrella Immunopharma, Inc., formerly known as TradeUP Acquisition Corp. ("UPTD") (NASDAQ:UPTD, UPTDW, UPTDU))), today announced the successful closing of its business combination with Estrella Biopharma, Inc. ("Estrella"), a preclinical-stage biopharmaceutical company developing T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. The resulting combined company will operate under the name Estrella Immunopharma, Inc. and will be led by Estrella Founder and CEO Dr. Cheng Liu. The com
NEW YORK, Sept. 18, 2023 /PRNewswire/ -- TradeUP Acquisition Corp. (the "Company" or "TradeUP") (NASDAQ:UPTD) today announced that, in order to extend the date by which the Company must complete its initial business combination from September 19, 2023 to October 19, 2023, for each public share that is not redeemed by the Company's stockholders in connection with such extension (collectively, the "Remaining Shares", each, a "Remaining Share"), the Company has deposited into its trust account (the "Trust Account") an aggregate of $37,432.70 (the "Monthly Extension Fee"), representing $0.05 per Remaining Share of the Company. The payment for such Monthly Extension Fee was made by Estrella Biop
NEW YORK, Aug. 18, 2023 /PRNewswire/ -- TradeUP Acquisition Corp. (the "Company" or "TradeUP") (NASDAQ:UPTD) today announced that, in order to extend the date by which the Company must complete its initial business combination from August 19, 2023 to September 19, 2023, for each public share that is not redeemed by the Company's stockholders in connection with such extension (collectively, the "Remaining Shares", each, a "Remaining Share"), the Company has deposited into its trust account (the "Trust Account") an aggregate of $37,432.70 (the "Monthly Extension Fee"), representing $0.05 per Remaining Share of the Company. The payment for such Monthly Extension Fee was made by Estrella Biophar
SC 13D - Estrella Immunopharma, Inc. (0001844417) (Subject)
SC 13G/A - TradeUP Acquisition Corp. (0001844417) (Subject)
SC 13G/A - TradeUP Acquisition Corp. (0001844417) (Subject)